Home Featured Page 162

Featured

Latest

Pα+ Psychedelic Bulletin #215: FDA’s Move to Single-Trial Approvals; Freedom to Heal Act Looks to Unlock Right to Try Psychedelics; Compass Clarifies Q1 Readout...

The View from D.C.: Psychedelic Politics, Blockers and Approvals on the Horizon

Logan Davidson – American Ibogaine, State Strategy, and the Future of Psychedelic Policy

Areyto Boriken – Ethnobotanical Adventure

The Ram Dass Institute of Psychedelic Studies with The Dying Inaugural Event on Maui

Numinus to Host Q3 2022 Results Conference Call on July 14,...

Algernon Pharmaceuticals Discloses Novel DMT Salt Patent Strategy Includes Bioactive Nicotinate...

FILAMENT HEALTH ANNOUNCES SIXTH PATENT ISSUANCE

Mindset Pharma Receives Allowance for Patent Application Covering its Short-Duration Novel...

BetterLife Secures Additional Mitacs Funding in Collaboration with Carleton University Research...

PT334 – Prof. David Nutt – The Human Brain, Addiction, and...

PharmaTher Announces Positive Results from Study For Ketamine Microneedle Patch

Psychedelic Bulletin #109 – California Decrim. Back on the Agenda; Reanalysis...

PT333 – Miriam Volat, MS & T. Cody Swift, MFT –...

FILAMENT HEALTH ANNOUNCES PRIVATE PLACEMENT OF UNITS AND CONVERTIBLE DEBENTURE UNITS...

1...161162163...303 Page 162 of 303

Pα+ Psychedelic Bulletin #215: FDA’s Move to Single-Trial Approvals; Freedom to...

The View from D.C.: Psychedelic Politics, Blockers and Approvals on the...

Logan Davidson – American Ibogaine, State Strategy, and the Future of...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.